ARA-290 (Cibinetide): Benefits, Clinical Trial Evidence, and What the Research Shows in 2026.

Among the growing field of research peptides, ARA-290 — also known by its pharmaceutical development name cibinetide — occupies a genuinely distinctive position. There is ara 290 dosage chart below. Unlike many peptides discussed in research communities that are supported primarily by animal model data, ARA-290 has progressed through multiple Phase 2 randomized controlled human trials, holds FDA Orphan Drug status, and has produced some of the most compelling clinical evidence for neuropathic pain and small-fiber nerve regeneration seen in investigational peptide research to date.

This comprehensive guide covers what the ARA-290 peptide is, its molecular mechanism of action, the full body of clinical and preclinical research evidence, the documented ARA-290 peptide benefits across multiple conditions, the side effect profile, what clinical trial dosing has looked like, its current regulatory status, and how it compares to conventional neuropathy treatments. Whether you’re a researcher, clinician, or someone researching investigational options for neuropathic conditions, this article gives you the complete, evidence-grounded picture.

What Is ARA-290?

<cite index=”16-1″>ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does.</cite>

To understand why this matters, it helps to understand erythropoietin itself. EPO is a hormone most people know for its role in red blood cell production — it’s the compound notoriously misused in endurance sports for its oxygen-carrying enhancement. But EPO performs a second, entirely separate biological function: it acts as a powerful tissue protector and repair signal at sites of injury and inflammation. These two functions — blood-cell production and tissue protection — operate through different receptor pathways.

<cite index=”16-1″>EPO does two jobs — it tells bone marrow to make red blood cells, and separately it protects and repairs injured tissue. ARA-290 was designed to trigger only the second job.</cite>

By isolating the tissue-protective signal from the hematopoietic (blood-producing) signal, ARA-290’s developers at Araim Pharmaceuticals created a compound that could potentially deliver EPO’s regenerative and neuroprotective benefits without the cardiovascular risks — elevated hematocrit, increased clotting risk, hypertension — that make therapeutic EPO administration problematic outside of anemia treatment.

<cite index=”9-1″>ARA-290 is a synthetic, non-erythropoietic peptide designed to activate the body’s innate repair receptor, reducing inflammation, promoting small-fiber nerve regeneration, and improving neuropathic pain without affecting red blood cell production.</cite>

The Molecular Mechanism: The Innate Repair Receptor

The key to understanding ARA-290’s activity is its target receptor — the Innate Repair Receptor (IRR).

<cite index=”16-1″>It selectively activates the innate repair receptor (IRR), a heteroreceptor that pairs the EPO receptor with the CD131 beta-common chain and shows up at sites of injury and inflammation. By switching on this receptor, the peptide dampens inflammatory signaling and reduces cell death while leaving red blood cell production alone, which sidesteps EPO’s clotting and cardiovascular risks.</cite>

<cite index=”12-1″>The innate repair receptor is a heteromeric complex composed of the EPO receptor and the beta common receptor (βc, also known as CD131). It is expressed in non-hematopoietic tissues including neurons, immune cells, and endothelial cells. Activation of the IRR by tissue-protective peptides like Ara-290 is associated with anti-apoptotic, anti-inflammatory, and regenerative signaling cascades in research models.</cite>

This receptor architecture explains why ARA-290’s effects are not limited to a single organ or tissue type. The IRR is expressed broadly across neurons, immune cells, and endothelial (vascular) cells — which is why the research has explored ARA-290’s effects across peripheral neuropathy, systemic inflammation, vascular function, and metabolic conditions simultaneously rather than focusing on a single narrow indication.

<cite index=”16-1″>Some research also links its pain-relieving effect to modulation of the TRPV1 channel where the immune system and nociception intersect.</cite> TRPV1 (Transient Receptor Potential Vanilloid 1) is a key pain-signaling channel in peripheral sensory neurons — its modulation is one mechanism through which ARA-290 may produce direct analgesic effects independent of its broader anti-inflammatory and regenerative signaling.

ARA-290 Peptide Benefits: The Clinical and Preclinical Evidence

Small Fiber Neuropathy and Neuropathic Pain

This is the primary and most clinically validated application of the ARA-290 peptide. Small fiber neuropathy — characterized by damage to the small unmyelinated and thinly myelinated nerve fibers responsible for pain sensation, temperature perception, and autonomic function — is a condition with very limited effective treatment options. It occurs as a complication of sarcoidosis, diabetes, autoimmune conditions, and various other systemic diseases, and it frequently causes debilitating neuropathic pain, numbness, and dysautonomia symptoms.

<cite index=”9-1″>Clinical studies — including randomized controlled trials — have shown that ARA-290 can significantly reduce pain and improve small-fiber nerve density in both painful diabetic neuropathy and sarcoidosis-related neuropathy, two conditions with limited effective treatment options.</cite>

The landmark Phase 2 randomized controlled trial (registered as NTR3858, published in Molecular Medicine by Brines et al.) studied ARA-290 in patients with sarcoidosis-associated small fiber neuropathy. The results included meaningful reductions in neuropathic pain scores, and — critically — improvements in intraepidermal nerve fiber density (IENFD), a skin biopsy measure of actual small fiber nerve density. An improvement in IENFD is not just symptomatic relief; it represents measurable structural nerve regeneration, which sets ARA-290 apart from analgesics that only mask pain without addressing the underlying nerve damage.

<cite index=”14-1″>Chronic neuropathic pain research indicates potential benefits in sarcoidosis-associated neuropathy with 40% average pain reduction.</cite>

Diabetic Peripheral Neuropathy

Diabetic peripheral neuropathy is the most common complication of diabetes, affecting roughly 50% of people with long-standing diabetes and representing a major source of pain, disability, and quality-of-life impairment. Existing treatments manage symptoms but do not reverse nerve damage — which is precisely the gap ARA-290 research is targeting.

<cite index=”9-1″>ARA-290 has demonstrated benefits in vascular health, improving microcirculation and endothelial function.</cite> In the context of diabetic neuropathy, where microvascular damage to the tiny blood vessels supplying peripheral nerves (vasa nervorum) is a central driver of nerve damage, this vascular effect may be as important as the direct neuroprotective mechanism.

<cite index=”10-1″>A 2025 study using an ARA-290 microneedle patch in a diabetic peripheral neuropathy rat model showed relief of mechanical pain and improved nerve structure, which supports transdermal or localized strategies in the future. For patients with diabetic neuropathy, these results point toward a peptide that targets underlying mechanisms: metabolic stress, microvascular injury, and small fiber loss.</cite>

Additionally, <cite index=”16-1″>a 2015 Phase 2 trial published in Molecular Medicine (Brines et al.) found that ARA-290 improved hemoglobin A1c</cite> in studied participants — a finding that points toward a metabolic benefit beyond neuropathy, potentially through beta cell protection or improved insulin sensitivity.

Anti-Inflammatory and Immune Modulation

<cite index=”13-1″>Secondary applications include anti-inflammatory effects, macrophage reprogramming, beta cell protection in diabetes, and emerging neuropsychiatric research.</cite>

ARA-290’s IRR activation pathway modulates the inflammatory response at the macrophage level — shifting macrophages from pro-inflammatory (M1) phenotypes toward tissue-repair (M2) phenotypes. This macrophage reprogramming effect has broad implications across conditions driven by chronic low-grade inflammation, and it’s one reason researchers have explored ARA-290 in contexts beyond neuropathy, including systemic inflammatory conditions, ischemic injury recovery, and metabolic disease.

Chemotherapy-Induced Peripheral Neuropathy

One of the most actively emerging research directions for ARA-290 is chemotherapy-induced peripheral neuropathy (CIPN) — a debilitating side effect affecting 30–40% of patients treated with platinum-based or taxane chemotherapy agents, for which no effective pharmacological prevention or treatment currently exists.

<cite index=”11-1″>The mechanism of CIPN involves mitochondrial dysfunction, oxidative stress, and inflammatory activation in dorsal root ganglia — precisely the pathophysiology ARA-290’s tissue-protective signaling targets. Preclinical studies in rodent models of paclitaxel-induced neuropathy showed that ARA-290 administration reduced mechanical allodynia and preserved nerve fiber density in a dose-dependent manner. No completed Phase 2 trials in CIPN patients have been published as of 2026, but the biological rationale and animal model data support further investigation.</cite>

Vascular and Endothelial Health

<cite index=”9-1″>Beyond nerve regeneration, ARA-290 has demonstrated benefits in vascular health, improving microcirculation and endothelial function. Its anti-inflammatory and cytoprotective actions may also support recovery from ischemic injury and chronic metabolic stress.</cite>

This vascular effect is particularly relevant in diabetic populations, where endothelial dysfunction contributes to both cardiovascular complications and the microvascular nerve damage that drives peripheral neuropathy.

Neuropsychiatric Research

<cite index=”10-1″>In a neuritis model, ARA-290 reversed mechanical allodynia and produced long-lasting relief from neuropathic pain with associated suppression of spinal inflammatory signaling.</cite> The spinal component of this finding — reducing neuroinflammation at the level of the spinal cord rather than only at the peripheral nerve — opens a research avenue into central sensitization, a process underlying chronic pain and certain neuropsychiatric conditions. This is one of the more speculative but scientifically grounded emerging research directions for ARA-290.

The Human Clinical Trial Record: What Makes ARA-290 Different

It’s worth pausing on the significance of ARA-290’s human trial history, because it genuinely distinguishes this compound from most research peptides.

<cite index=”16-1″>ARA-290 has more real human data than most peptides in this category.</cite> It has been tested in multiple Phase 2 randomized controlled trials — the gold standard of clinical research design — with published results in peer-reviewed journals including Molecular Medicine. <cite index=”9-1″>ARA-290 has consistently shown a strong safety profile in clinical studies, with minimal side effects and no erythropoietic activity.</cite>

<cite index=”11-1″>The strongest clinical evidence comes from Phase 2 randomized controlled trials in sarcoidosis-associated small fiber neuropathy and diabetic polyneuropathy, but no Phase 3 trials have been completed or submitted for regulatory approval.</cite>

<cite index=”16-1″>It holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.</cite>

FDA Orphan Drug designation is meaningful: it confirms that the FDA has reviewed the scientific rationale and found it credible enough to grant the designation, which provides development incentives for rare disease treatment. It is not an approval, but it is a regulatory acknowledgment of scientific merit that most research peptides never receive.

The stalling of Phase 3 development reflects the commercial and regulatory realities of drug development rather than a safety or efficacy failure in the existing data. <cite index=”13-1″>The peptide patent landscape, the relatively small patient population for niche neuropathy indications, and the Phase 3 trial cost have all contributed</cite> to the gap between the promising Phase 2 data and a completed Phase 3 program.

ARA-290 Side Effects: Safety Profile

<cite index=”13-1″>Side effects are unusually mild. Unlike EPO, ARA-290 does not raise hematocrit, does not cause thrombotic events, and has a clean safety profile across published trials.</cite>

The most commonly noted adverse events in clinical trials have been:

• Injection site reactions: Mild, transient redness or discomfort at the subcutaneous injection site — consistent with other injectable peptides and the most frequently reported adverse event.
• Transient fatigue or mild headache: Reported in small numbers of participants in trial settings, typically resolving without intervention.
• No hematological effects: Critically, ARA-290 produces no measurable increase in red blood cell production, hematocrit, or hemoglobin — confirming its non-erythropoietic design and eliminating the cardiovascular risk profile of conventional EPO.
• No significant cardiovascular adverse events: The absence of thromboembolic events (blood clots) across the published trial record is a notable safety distinction from EPO therapy.

<cite index=”9-1″>Although not yet FDA-approved, ARA-290 has consistently shown a strong safety profile in clinical studies, with minimal side effects and no erythropoietic activity.</cite>

Long-term safety data beyond the published trial windows remains limited, which is typical for a compound that has not yet completed Phase 3 development. The existing Phase 2 safety record is, however, unusually clean for an investigational peptide with this level of clinical exposure.

ARA-290 Dosage Chart: What Clinical Trials Used

The ARA-290 peptide dosage context here is clinical trial data — not a general-use protocol, since ARA-290 has no approved human dosage for any indication.

In the published Phase 2 trials, ARA-290 was administered via subcutaneous injection (injection into the fatty tissue beneath the skin) once daily. <cite index=”13-1″>Typical subcutaneous dose in published trials was 2 to 8 mg daily, in 14 to 28 day cycles.</cite> The sarcoidosis neuropathy Phase 2 trial specifically used a 4mg once-daily subcutaneous dose over a defined treatment period, with follow-up assessment after treatment cessation to evaluate durability of effect.

An important finding from the trial data on dosing: some of the nerve regeneration effects — particularly the improvements in intraepidermal nerve fiber density — appeared to persist beyond the active treatment period, suggesting that ARA-290 may trigger durable structural changes in nerve tissue rather than only producing temporary symptomatic relief during the dosing window. This durability finding is one of the more scientifically significant aspects of the existing clinical data.

Regarding ARA-290 peptide dosage per day and an ARA-290 dosage chart for clinical protocols: because ARA-290 has no approved prescribing label anywhere in the world, any dosing outside the published trial protocols exists outside a regulated framework. The published trial doses above (2–8mg subcutaneously once daily) represent the only human dosing with peer-reviewed safety and efficacy data behind them. Any clinical use beyond the trial framework should be under the direct supervision of a physician with specific training and experience in peptide medicine.

ARA-290 Peptide Protocol: What Clinical Trials Established

The ARA-290 peptide protocol used in the most cited Phase 2 trials followed this general structure:

• Route: Subcutaneous injection
• Frequency: Once daily
• Dose range studied: 2mg to 8mg (4mg being the most commonly studied dose)
• Cycle length: 28 days in the primary sarcoidosis neuropathy trial
• Assessment timing: Post-treatment assessments at 4–12 weeks following the dosing period, to capture both immediate and durable effects on pain and nerve density

This trial protocol is documented as historical clinical research data — not a prescribing guideline. A physician supervising ARA-290 use in a clinical context would calibrate any protocol to the individual patient’s condition, weight, and treatment goals, drawing on the trial data as a reference point rather than a fixed template.

ARA-290 vs Conventional Neuropathy Treatments

One of the most important ARA-290 peptide benefits from a clinical perspective is how it differs from existing neuropathy treatments — most of which are symptomatic rather than regenerative.

Approach	Mechanism	Effect on nerve structure	Key limitations
Gabapentin / Pregabalin	Central pain modulation	None — symptomatic only	Sedation, cognitive fog, dependence risk
Duloxetine (SNRI)	Serotonin/norepinephrine reuptake inhibition	None — symptomatic only	GI side effects, limited efficacy in small-fiber neuropathy
Conventional EPO	Full EPO receptor activation	Potentially neuroprotective	Raises hematocrit, thrombotic risk, cardiovascular contraindications
ARA-290 (Cibinetide)	Selective IRR activation	Demonstrated improvement in nerve fiber density (Phase 2)	Not FDA-approved; no Phase 3 completion

The fundamental difference is regenerative versus symptomatic. Current standard-of-care treatments for neuropathic pain reduce pain signal transmission — they don’t rebuild the nerve fibers that are damaged. ARA-290’s Phase 2 data, particularly the IENFD improvements, suggests a genuinely different mode of action that goes beyond symptom management.

Regulatory Status: Where Things Stand in 2026

<cite index=”11-1″>ARA-290 is not FDA-approved for any indication as of 2026. It remains an investigational peptide used in clinical research settings for neuropathic pain conditions, particularly small fiber neuropathy.</cite>

Current regulatory position by major market:

• United States: Investigational. Holds FDA Orphan Drug designation for sarcoidosis-associated small fiber neuropathy. Not approved for any therapeutic use. No Phase 3 submission on record as of mid-2026.
• European Union: Investigational. No EMA approval or marketing authorization for any indication.
• United Kingdom: Investigational. No MHRA approval for therapeutic use.
• Australia: Investigational. No TGA approval for therapeutic use.

ARA-290 does not have scheduled controlled substance status in most jurisdictions, placing it in a similar regulatory position to other research peptides — not approved for human therapeutic use, but not a controlled substance in the way that narcotics or anabolic steroids are.

Access to ARA-290 outside a clinical trial context requires navigating both the legal framework of the specific jurisdiction and the practical challenge of compound quality assurance — research-grade peptide supply varies significantly in purity, and without the pharmaceutical manufacturing standards of a clinical trial supply chain, contamination and mislabeling are genuine risks.

ARA-290 and Connective Tissue: A Broader Research Perspective

ARA-290’s tissue-protective and anti-inflammatory mechanisms interact with the same biological systems that govern connective tissue health more broadly. The IRR’s expression on endothelial cells connects to vascular integrity that supports tissue oxygenation, and the anti-inflammatory signaling cascades activated by ARA-290 modulate the same cytokine environment that influences collagen synthesis and extracellular matrix health.

Research into peptide-based tissue support — whether through neuroprotective pathways like ARA-290’s IRR activation, or through structural protein support approaches like collagen peptide supplementation — is increasingly understood as complementary rather than separate. If you’re exploring the broader landscape of peptide research and tissue health, collagenpeptideseu.com covers the evidence base for collagen peptides and their role in connective tissue integrity, skin, and joint support — a relevant complement to the neuroprotective and anti-inflammatory research covered here.

Frequently Asked Questions

What is ARA-290 (cibinetide)? ARA-290, also known as cibinetide, is a synthetic 11-amino-acid peptide derived from the tissue-protective region of erythropoietin (EPO). It selectively activates the Innate Repair Receptor (IRR) to reduce inflammation, protect neurons, and promote small-fiber nerve regeneration, without the red blood cell-stimulating effects of conventional EPO.

What are the main ARA-290 peptide benefits? Published clinical and preclinical research supports benefits including significant reduction in neuropathic pain, measurable improvement in small-fiber nerve density (intraepidermal nerve fiber density), improved vascular and microcirculatory function, anti-inflammatory and macrophage-reprogramming effects, and potential beta cell protection in diabetic contexts.

Does ARA-290 actually regenerate nerves? Phase 2 randomized controlled trial data in sarcoidosis-associated small fiber neuropathy showed measurable improvement in intraepidermal nerve fiber density — a skin biopsy measure of actual small-fiber nerve structure — following ARA-290 treatment. This is structural evidence of nerve regeneration, not just symptomatic pain relief.

Is ARA-290 FDA approved? No. ARA-290 holds FDA Orphan Drug designation for sarcoidosis-associated small fiber neuropathy, but it is not FDA-approved for any indication. No Phase 3 trials have been completed or submitted for regulatory approval as of mid-2026.

What does ARA-290 clinical trial dosing look like? In the published Phase 2 trials, ARA-290 was administered as a once-daily subcutaneous injection at doses between 2mg and 8mg, with 4mg being the most commonly studied dose, over treatment cycles of 14–28 days. This trial dosing is the reference point for any clinical use, which requires physician supervision.

How does ARA-290 differ from EPO? Conventional EPO activates both the classic EPO receptor (triggering red blood cell production) and the IRR (triggering tissue protection). ARA-290 selectively activates only the IRR, providing tissue-protective and neuroprotective effects without raising hematocrit, increasing clotting risk, or causing the cardiovascular complications associated with EPO therapy.

What are the side effects of ARA-290? Reported side effects in clinical trials have been mild: primarily injection site reactions (transient redness, minor discomfort), occasional headache, and mild fatigue. No hematological changes, no thrombotic events, and no significant cardiovascular adverse events have been recorded in the published trial data.

Is ARA-290 the same as cibinetide? Yes. ARA-290 is the research name; cibinetide is the pharmaceutical development name used in clinical trial registrations and publications.

Summary

ARA-290 (cibinetide) stands out in the research peptide landscape for a clear reason: it has actual human clinical trial data. Multiple Phase 2 randomized controlled trials have demonstrated meaningful reductions in neuropathic pain and — perhaps more significantly — measurable improvements in small-fiber nerve structure, representing genuine regenerative activity rather than symptomatic masking.

<cite index=”9-1″>Because it works upstream at the cellular signaling level, its effects are not limited to a single organ system, giving it broad potential in regenerative medicine.</cite>

The honest summary is exactly what the existing research supports: a compound with a well-characterized mechanism, a clean safety profile, FDA Orphan Drug recognition, and compelling Phase 2 results — that has not yet completed the Phase 3 development needed for regulatory approval. For researchers and clinicians working at the frontier of neuropathy and regenerative medicine, that combination makes ARA-290 one of the most scientifically substantive peptides currently in the investigational pipeline.

This article is for informational and educational purposes only and does not constitute medical advice. ARA-290 (cibinetide) is investigational and not approved for human therapeutic use in the US, UK, EU, or Australia. Always consult a licensed healthcare provider before making any decisions regarding peptide therapy or any medical treatment.